Revance will wait to seek backing for Botox-rival

Revance Therapeutics Inc will wait to seek partnerships with bigger drugmakers until it is closer to regulatory approval for its Botox rival treatment, Chief Executive Dan Browne told Reuters in an interview. The California-based drug developer shook the aesthetic industry last week by reporting data that showed its drug RT002 reduced the severity of frown lines for about six months, almost double the 3-4 months Botox and other treatments achieve. The news sent a shiver through investors who have bet on Botox owner Allergan Plc and its development strategy, which relies heavily on the popularity of the treatment both in cosmetic and therapeutic procedures.